Methodological Guidelines of the Scientific Community for Human Microbiome Research (CHMR) and the Russian Gastroenterology Association (RGA) on the Use of Probiotics, Prebiotics, Synbiotics, Metabiotics and Functional Foods Enriched with Them for the Treatment and Prevention of Gastrointestinal Diseases in Adults and Children

   Aim: to optimize outcomes of the treatment and prevention of gastrointestinal diseases in adults and children.

   Key points. The Methodological Guidelines contain sections on the terminology, classification, mechanisms of action, requirements for sale in the Russian Federation, requirements for proving the efficacy and safety of probiotics, prebiotics, synbiotics and metabiotics, as well as functional foods enriched with them. An overview of relevant data allowing to include these drugs and products in the treatment an d prevention of gastrointestinal diseases in adults and children is presented.

   Conclusion. The clinical efficacy of probiotics, prebiotics, synbiotics and metabiotics depends on the specificity and quantity of their components, the dosage form, the regimen and duration of treatment. Products and functional foods with proven efficacy and safety are recommended for the treatment and prevention of gastrointestinal diseases in adults and children.

1. World Gastroenterology Organisation. Probiotics and prebiotics. 2023. URL: https://www.worldgastroenterology.org/guidelines

2. Davani-Davari D., Negahdaripour M., Karimzadeh M., Seifan M., Mohkam M., Masoumi S. J., et al. Prebiotics: Definition, types, sources, mechanisms, and clinical applications. Foods. 2019;8(3):92. DOI: 10.3390/foods8030092

3. Swanson K.S., Gibson G.R., Hutkins R., Reimer R.A., Reid G., Verbeke K., et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol. 2020;17(11):687–701. DOI: 10.1038/s41575-020-0344-2

4. Ma L., Tu H., Chen T. Postbiotics in human health : A narrative review. Nutrients. 2023;15(2):291. DOI: 10.3390/nu15020291

5. Salminen S., Collado M.C., Endo A., Hill C., Lebeer S., Quigley E.M.M., et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18(9):649–67. DOI: 10.1038/s41575-021-00440-6

6. Asif A., Afzaal M., Shahid H., Saeed F., Ahmed A., Shah Y.A., et al. Probing the functional and therapeutic properties of postbiotics in relation to their industrial application. Food Sci Nutr. 2023;11(8):4472–84. DOI: 10.1002/fsn3.3465

7. Thorakkattu P., Khanashyam A.C., Shah K., Babu K.S., Mundanat A.S., Deliephan A., et al. Postbiotics: Current trends in food and pharmaceutical industry. Foods. 2022;11(19):3094. DOI: 10.3390/foods11193094

8. Plaza-Diaz J., Ruiz-Ojeda F.J., Gil-Campos M., Gil A. Mechanisms of action of probiotics. Adv Nutr. 2019;10(Suppl 1):S49–66. DOI: 10.1093/advances/nmy063

9. Halloran K., Underwood M.A. Probiotic mechanisms of action. Early Hum Dev. 2019; 135:58–65. DOI: 10.1016/j.earlhumdev.2019.05.010

10. Hernández-Mendoza A., González-Córdova A.F., Martínez-Porchas M. Influence of probiotics on the animal gut microbiota and their impact on the bioavailability of toxic agents: An opinion paper. Front Nutr. 2022;9:870162. DOI: 10.3389/fnut.2022.870162

11. Martin-Gallausiaux C., Marinelli L., Blottière H.M., Larraufie P., Lapaque N. SCFA: Mechanisms and functional importance in the gut. Proc Nutr Soc. 2021;80(1):37–49. DOI: 10.1017/S0029665120006916

12. Dicks L.M.T. Gut bacteria and neurotransmitters. Microorganisms. 2022;10(9):1838. DOI: 10.3390/microorganisms10091838

13. Barone M., D'Amico F., Brigidi P., Turroni S. Gut microbiome-micronutrient interaction: The key to controlling the bioavailability of minerals and vitamins? Biofactors. 2022;48(2):307–14. DOI: 10.1002/biof.1835

14. Potrykus M., Czaja-Stolc S., Stankiewicz M., Kaska Ł., Małgorzewicz S. Intestinal microbiota as a contributor to chronic inflammation and its potential modifications. Nutrients. 2021;13(11):3839. DOI: 10.3390/nu13113839

15. Han S., Lu Y., Xie J., Fei Y., Zheng G., Wang Z., et al. Probiotic gastrointestinal transit and colonization after oral administration: A long journey. Front Cell Infect Microbiol. 2021;11:609722. DOI: 10.3389/fcimb.2021.609722

16. Duncan S.H., Conti E., Ricci L., Walker A.W. Links between diet, intestinal anaerobes, microbial metabolites and health. Biomedicines. 2023;11(5):1338. DOI: 10.3390/biomedicines11051338

17. Valentino V., Magliulo R., Farsi D., Cotter P.D., O'Sullivan O., Ercolini D., et al. Fermented foods, their microbiome and its potential in boosting human health. Microb Biotechnol. 2024;17(2):e14428. DOI: 10.1111/1751-7915.14428

18. Roe A.L., Boyte M.E., Elkins C.A., Goldman V.S., Heimbach J., Madden E., et al. Considerations for determining safety of probiotics: A USP perspective. Regul Toxicol Pharmacol. 2022;136:105266. DOI: 10.1016/j.yrtph.2022.105266

19. Trush E.A., Poluektova E.A., Beniashvilli A.G., Shifrin O.S., Poluektov Y.M., Ivashkin V.T. The evolution of human probiotics: Challenges and prospects. Probiotics Antimicrob Proteins. 2020;12(4):1291–9. DOI: 10.1007/s12602-019-09628-4

20. Tsai Y.L., Lin T.L., Chang C.J., Wu T.R., Lai W.F., Lu C.C., et al. Probiotics, prebiotics and amelioration of diseases. J Biomed Sci. 2019;26(1):3. DOI: 10.1186/s12929-018-0493-6

21. Wang Y., Jiang Y., Deng Y., Yi C., Wang Y., Ding M., et al. Probiotic supplements: Hope or hype? Front Microbiol. 2020;11:160. DOI: 10.3389/fmicb.2020.00160

22. Malagón-Rojas J.N., Mantziari A., Salminen S., Szajewska H. Postbiotics for preventing and treating common infectious diseases in children : A systematic review. Nutrients. 2020;12(2):389. DOI: 10.3390/nu12020389

23. Storr M., Stengel A. Systematic review: Clinical evidence of probiotics in the prevention of antibiotic-associated diarrhoea. MMW Fortschr Med. 2021;163(Suppl 4):19–26. (In German). DOI: 10.1007/s15006-021-9762-5

24. Darbandi A., Banar M., Koupaei M., Afifirad R., Asadollahi P., Bafandeh E., et al. Clinical efficacy of probiotics in prevention of infectious diseases among hospitalized patients in ICU and non-ICU wards in clinical randomized trials : A systematic review. Health Sci Rep. 2023;6(8):e1469. DOI: 10.1002/hsr2.1469

25. Drozdov V.N., Shikh E.V., Astapovskii A.A., Khalaidzheva K.N., Solovieva S.A., Dorogun O.B. Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea and antibiotic-associated diarrhea. Problems of Nutrition. 2023;92(4):92–103. (In Russ.) DOI: 10.33029/0042-8833-2023-92-4-92-103

26. Bhalla A. Randomized placebo-controlled, double blind, multicentric trial on efficacy and safety of Providac techsules (Lactobacillus acidophilus LA-5 and bifidobacterium BB-12) for prevention of antibiotic associated diarrhea in Indian patients. J Clin Pharmacol. 2011;51(9):1327. DOI: 10.1177/0091270010418046

27. Madoff S.E., Urquiaga M., Alonso C.D., Kelly C.P. Prevention of recurrent Clostridioides difficile infection : A systematic review of randomized controlled trials. Anaerobe. 2020;61:102098. DOI: 10.1016/j.anaerobe.2019.102098

28. Wombwell E., Patterson M.E., Bransteitter B., Gillen L.R. The effect of Saccharomyces boulardii primary prevention on risk of hospital-onset Clostridioides difficile infection in hospitalized patients administered antibiotics frequently associated with C. difficile infection. Clin Infect Dis. 2021;73(9):e2512–8. DOI: 10.1093/cid/ciaa808

29. Helmy Y.A., Taha-Abdelaziz K., Hawwas H.A.E., Ghosh S., AlKafaas S.S., Moawad M.M.M., et al. Antimicrobial resistance and recent alternatives to antibiotics for the control of bacterial pathogens with an emphasis on foodborne pathogens. Antibiotics (Basel). 2023;12(2):274. DOI: 10.3390/antibiotics12020274

30. Parth K., Prudhivi R., Palatheeya S., Abbas S.K., Varsha K., Niharika B.V., et al. Efficacy of Lactobacillus reuteri supplementation in eradication of H. pylori: A comparison study with triple drug therapy. J Pharm Res Int. 2021;33(52B):151–9. DOI: 10.9734/JPRI/2021/v33i52B33611

31. Seddik H., Boutallaka H., Elkoti I., Nejjari F., Berraida R., Berrag S., et al. Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: A randomized, open-label trial. Eur J Clin Pharmacol. 2019l;75(5):639–45. DOI: 10.1007/s00228-019-02625-0

32. Ivashkin V.Т., Ulyanin A.I., Mayev I.V., Kozlov R.S., Livzan M.A., Abdulkhakov S.R., et al. Modern approaches to H. pylori eradication therapy in adults (literature review and resolution of Experts Council). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(6):7–19. (In Russ.) DOI: 10.22416/1382-4376-2022-32-6-7-19

33. Yakovenko E.P., Strokova T.V., Yakovenko A.V., Ivanov A.N., Soluyanova I.P., Vasilyev N.N. A prospective randomized comparative study of the efficacy and safety of a two-week bismuth-based quadrotherapy of Helicobacter pylori infection with the inclusion of the probiotic containing Bifidobacterium longum BB-46 and Enterococcus faecium ENCfa-68. Terapevticheskii arkhiv. 2021;93(8):916–22. (In Russ.) DOI: 10.26442/0040366.2021.08.200996

34. McFarland L.V., Karakan T., Karatas A. Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome : A systematic review and meta-analysis. EClinicalMedicine. 2021;41:101154. DOI: 10.1016/j.eclinm.2021.101154

35. Xie P., Luo M., Deng X., Fan J., Xiong L. Outcome-specific efficacy of different probiotic strains and mixtures in irritable bowel syndrome : A systematic review and network meta-analysis. Nutrients. 2023;15(17):3856. DOI: 10.3390/nu15173856

36. Chlebicz-Wójcik A., ólióewska K. Probiotics, prebiotics, and synbiotics in the irritable bowel syndrome treatment : A review. Biomolecules. 2021;11(8):1154. DOI: 10.3390/biom11081154

37. Ivashkin V.T., Kudryavtseva A.V., Krasnov G.S., Poluektov Y.M., Morozova M.A., Shifrin O.S., et al. Efficacy and safety of a food supplement with standardized menthol, limonene, and gingerol content in patients with irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial. PloS One. 2022;17(6):e0263880. DOI: 10.1371/journal.pone.0263880

38. Khlinov I.B., Khlynova R.I., Voronova E.I., Garanina E.V., Gurikova I.A., Kobzar T.I., et al. Efficacy and safety of Lactobacillus paracasei CNCM I-1572 and fructooligosaccharides in the treatment of patients with irritable bowel syndrome with constipation. Experimental and Clinical Gastroenterology. 2021;190(6):57–62. (In Russ.) DOI: 10.31146/1682-8658-ecg-190-6-57-62

39. Akhmedov V.A., Gaus O.V. Possibilities of modern probiotic therapy in the treatment of patients with post-infectious irritable bowel syndrome. Lechaschi Vrach. 2022;2(25):32–5. (In Russ.) DOI: 10.51793/OS.2022.25.2.005

40. Ivashkin V.T., Maev I.V., Alekseeva O.P., Alekseenko S.A., Korochanskaya N.V., Poluektova E.A., et al. Determination of probiotics prescription indications in patients with irritable bowel syndrome (materials of the Expert Council and literature review). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(2):9–18. (In Russ.) DOI: 10.41.

41. Iancu M.A., Profir M., Roşu O.A., Ionescu R.F., Cretoiu S.M., Gaspar B.S. Revisiting the intestinal microbiome and its role in diarrhea and constipation. Microorganisms. 2023;11(9):2177. DOI: 10.3390/microorganisms11092177

42. Kang S.J., Cho Y.S., Lee T.H., Kim S.E., Ryu H.S., Kim J.W., et al.; Constipation Research Group of the Korean Society of Neurogastroenterology and Motility. Medical management of constipation in elderly patients : Systematic review. J Neurogastroenterol Motil. 2021;27(4):495–512. DOI: 10.5056/jnm20210

43. Rau S., Gregg A., Yaceczko S., Limketkai B. Prebiotics and probiotics for gastrointestinal disorders. Nutrients. 2024;16(6):778. DOI: 10.3390/nu16060778

44. McFarland L.V., Goh S. Are probiotics and prebiotics effective in the prevention of travellers' diarrhea : A systematic review and meta-analysis. Travel Med Infect Dis. 2019;27:11–19. DOI: 10.1016/j.tmaid.2018.09.007

45. Oyarzun I., Le Nevé B., Yañez F., Xie Z., Pichaud M., Serrano-Gómez G., et al. Human gut metatranscriptome changes induced by a fermented milk product are associated with improved tolerance to a flatulogenic diet. Comput Struct Biotechnol J. 2022;20:1632–41. DOI: 10.1016/j.csbj.2022.04.001

46. Le Nevé B., de la Torre A.M., Tap J., Derrien M., Cotillard A., Barba E., et al. A fermented milk product with B. lactis CNCM I-2494 and lactic acid bacteria improves gastrointestinal comfort in response to a challenge diet rich in fermentable residues in healthy subjects. Nutrients. 2020;12(2):320. DOI: 10.3390/nu1202032022416/1382-4376-2022-32-2-9-18

47. Lapinskii I.V., Serkova M.Yu., Bakulin I.G., Skalinskaya M.I., Avalueva E.B. Metabiotic based on metabolites of Bacillus subtilis for correction of gastrointestinal symptoms in patients with post-COVID syndrome. Medical alphabet. 2022;(35):8–14. (In Russ.) DOI: 10.1016/j.jceh.2021.12.007

48. Sahney A., Wadhawan M. Encephalopathy in cirrhosis: Prevention and management. J Clin Exp Hepatol. 2022;12(3);927–36. DOI: 10.1016/j.jceh.2021.12.007

49. Maslennikov R., Efremova I., Ivashkin V., Zharkova M., Poluektova E., Shirokova E., et al. Effect of probiotics on hemodynamic changes and complications associated with cirrhosis: A pilot randomized controlled trial. World J Hepatol. 2022;14(8):1667–77. DOI: 10.4254/wjh.v14.i8.1667

50. Dudanova O.P., Larina N.A., Shipovskaya A.A., Kurbatova I.V. Efficacy of the Bactimunal metabiotic (based on Bacillus subtilis) in non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2023;8:93–9. (In Russ.) DOI: 10.31146/1682-8658-ecg-216-8-93-99

51. Efremova I., Maslennikov R., Zharkova M., Poluektova E., Benuni N., Kotusov A., et al. Efficacy and safety of a probiotic containing Saccharomyces boulardii CNCM I-745 in the treatment of small intestinal bacterial overgrowth in decompensated cirrhosis: Randomized, placebo-controlled study. J Clin Med. 2024;13(3):919. DOI: 10.3390/jcm13030919

52. Ivashkin V.T., Fomin V.V., Tkacheva O.N., Medvedev O.S., Poluektova E.A., Abdulganieva D.I., et al. Small intestinal bacterial overgrowth in various specialties of medical practice (literature review and Expert Council resolution). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(2):14–34. (In Russ.) DOI: 10.22416/1382-4376-2024-34-2-14-34

53. McFarland L.V., Srinivasan R., Setty R.P., Ganapathy S., Bavdekar A., Mitra M., et al. Specific probiotics for the treatment of pediatric acute gastroenteritis in India : A systematic review and meta-analysis. JPGN Rep. 2021;2(3):e079. DOI: 10.1097/PG9.0000000000000079

54. Fu H., Li J., Xu X., Xia C., Pan Y. Effectiveness and safety of Saccharomyces boulardii for the treatment of acute gastroenteritis in the pediatric population : A systematic review and meta-analysis of randomized controlled trials. Comput Math Methods Med. 2022;2022:6234858. DOI: 10.1155/2022/6234858

55. Zanza C., Romenskaya T., Longhitano Y., Piccolella F., Racca F., Tassi M.F., et al. Probiotic bacterial application in pediatric critical illness as coadjuvants of therapy. Medicina (Kaunas). 2021;57(8):781. DOI: 10.3390/medicina57080781

56. Sutovskaya D.V., Litvinov D.I. The effectiveness of the use of synbiotics in the complex therapy of acute intestinal infections in children. Russian Pediatric Journal. 2023;26(6):426–9. (In Russ.) DOI: 10.46563/1560-9561-2023-26-6-426-429

57. Novokshonov A.A., Sokolova N.V., Galeyeva Ye.V., Krapivina I.V., Portnykh O.Yu. Probiotic Bifiform® is an alternative to etiotropic antibiotic and chemotherapy for acute intestinal infections in children. Children Infections. 2003;3:36–40. (In Russ.)

58. Feklisova L.V. Results of using the probiotic Acipol in children with various infectious pathologies. Pediatria. Journal named after G.N. Speransky. 2008;87(6):87–91. (In Russ.).

59. Al Sharaby A., Abugoukh T.M., Ahmed W., Ahmed S., Elshaikh A.O. Do probiotics prevent Clostridium difficile-associated diarrhea? Cureus. 2022;14(8):e27624

60. Kladova O.V., Ivashkina N.Yu., Shuster A.M., Martyanov V.A., Uchajkin V.F., Rusakova V.D., et al. Preventive and therapeutic effectiveness of Acipole® in case of antibiotic-associated diarrhea in children. Children Infections. 2009;8(1):44–7. (In Russ.)

61. Liu L.H., Han B., Tao J., Zhang K., Wang X.K., Wang W.Y. The effect of Saccharomyces boulardii supplementation on Helicobacter pylori eradication in children : A systematic review and meta-analysis of randomized controlled trials. BMC Infect Dis. 2023;23(1):878. DOI: 10.1186/s12879-023-08896-4

62. Meliț L.E., Mărginean C.O., Săsăran M.O. The challenges of eradicating pediatric Helicobacter pylori infection in the era of probiotics. Children (Basel). 2022;9(6):795. DOI: 10.3390/children9060795

63. Gurova M.M. The use of probiotic preparations to optimize the treatment of chronic gastroduodenitis. Pediatria. Journal named after G.N. Speransky. 2010;89(2):81–5. (In Russ.)

64. Collinson S., Deans A., Padua-Zamora A., Gregorio G.V., Li C., Dans L.F., et al. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2020;12(12):CD003048. DOI: 10.1002/14651858.CD003048.pub4

65. Chen K., Zhang G., Xie H., You L., Li H., Zhang Y., et al. Efficacy of Bifidobacterium animalis subsp. lactis, BB-12® on infant colic — a randomised, double-blinded, placebo-controlled study. Benef Microbes. 2021;12(6):531–40. DOI: 10.3920/BM2020.0233

66. Novikova V.P., Polunina A.V., Bannova S.L., Balashov A.L., Dudurich V.V., Danilov L.G., et al. Gastrointestinal tract in children with novel coronavirus infection and post-COVID-19 syndrome. The role of synbiotics for improving clinical symptoms, gut microbiota, and intestinal permeability. Russian Journal of Woman and Child Health. 2023;6(3):283–9. (In Russ.) DOI: 10.32364/2618-8430-2023-6-3-10

67. Vorobieva O.A., Shikh E.V., Drozdov V.N., Shikh N.V. The results of the use of a combined probiotic (Lactobacillus rhamnosus GG and Bifidobacterium animalis spp. lactis ВВ-12) in children with gastrointestinal and skin manifestations of food allergy. Voprosy pitaniia [Problems of Nutrition]. 2023;92(3):79–86. (In Russ.) DOI: 10.33029/0042-8833-2023-92-3-79-86

68. Makarova S.G., Emelyashenkov E.E., Fisenko A.P., Ereshko O.A., Gordeeva I.G., Yasakov D.S., et al. Synbiotics in complex therapy for atopic dermatitis and food allergy in children. Pediatric Nutrition. 2021;19(6):16–25. (In Russ.) DOI: 10.20953/1727--2021-6-16-25